The capacity of TheraVac to act as an antitumor vaccine is based on the activation of tDCs by the administered combination of R848 and HMGN1, which promotes tDC homing to draining lymph nodes for the induction of specific protective anti-tumor immune responses. This evidence concerns the gene HMGN1 and neoplasm.